Rein Therapeutics (RNTX) Enterprise Value (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Enterprise Value of -$4.4 million for Q1 2026, up 40.16% year-over-year from -$3.2 million in Q1 2025, and down 38.26% quarter-over-quarter from -$3.2 million in Q4 2025.
Rein Therapeutics (RNTX) Enterprise Value (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Enterprise Value for 11 consecutive years, with -$4.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 40.16% year-over-year to -$4.4 million; the TTM figure through Mar 2026 stood at -$4.4 million (up 40.16% YoY), while the FY2025 annual figure was -$3.2 million, up 75.01% from the prior year.
- Enterprise Value retreated to -$4.4 million in Q1 2026 per RNTX's latest filing, from -$3.2 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$3.2 million in Q4 2025 and bottomed at -$32.4 million in Q2 2022.
- Historically, Enterprise Value has averaged -$12.4 million across 5 years, with a median of -$12.1 million in 2024.
- On a YoY basis, Enterprise Value climbed as much as 88.64% in 2022 and fell as far as 233.99% in 2022.
- Rein Therapeutics' Enterprise Value stood at -$5.2 million in 2022, then sank by 232.69% to -$17.4 million in 2023, then advanced by 25.91% to -$12.9 million in 2024, then surged by 75.01% to -$3.2 million in 2025, then plunged by 38.26% to -$4.4 million in 2026.
- Business Quant data shows RNTX's Enterprise Value at -$4.4 million in Q1 2026, -$3.2 million in Q4 2025, and -$4.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.92 Bn | 53.78 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.70 Bn | 28.39 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.99 Bn | 9.60 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 2.12 Bn |
| 10 | Rein Therapeutics | 54.82 Mn | 54.82 Mn | - | -75.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -75.73 Mn |
| Mar 31, 2026 | -4.45 Mn |
| Dec 31, 2025 | -3.22 Mn |
| Sep 30, 2025 | -4.05 Mn |
| Jun 30, 2025 | -5.72 Mn |
| Mar 31, 2025 | -7.43 Mn |
| Dec 31, 2024 | -12.87 Mn |
| Sep 30, 2024 | -17.68 Mn |
| Jun 30, 2024 | -21.94 Mn |
| Mar 31, 2024 | -12.07 Mn |
| Dec 31, 2023 | -17.36 Mn |
| Sep 30, 2023 | -12.09 Mn |
| Jun 30, 2023 | -13.19 Mn |
| Mar 31, 2023 | -7.81 Mn |
| Dec 31, 2022 | -5.22 Mn |
| Sep 30, 2022 | -25.48 Mn |
| Jun 30, 2022 | -32.38 Mn |
| Mar 31, 2022 | -7.47 Mn |
| Dec 31, 2021 | -45.93 Mn |
| Sep 30, 2021 | -7.63 Mn |